• ARGX-113, an Investigational Therapy for Myasthenia Gravis, Shows Promise in Phase 2 Trial
  • Low-Dose Oral Corticosteroids Offer More Promising Outcomes for MG Patients than Higher Doses
  • Phase 1 Trial of GTP-004 Initiated as Therapy for Myasthenia Gravis Treatment Side Effects
  • Opdivo May Increase Risk for Autoimmune Disorders in Cancer Patients, Case Report Suggests
  • Myasthenia Gravis Foundation’s Upcoming MG Walks Raise Funds and Awareness
  • Assistance Fund Opens Co-Pay Program for Myasthenia Gravis Patients
  • Study Explains Why MuSK MG Patients Relapse After Rituxan Therapy
  • Rare Disease Patient Groups Unite to Preserve Orphan Drug Tax Credit in US
  • Cognitive Behavioral Therapy Could Help MG Patients with Anxiety, Depression or Insomnia
  • Relatives of Myasthenia Gravis Patients More Prone to Developing the Disease, Study Suggests
  • Alexion Receives Extended Patent in Japan for Soliris (Eculizumab)
  • Tetanus Vaccine Does Not Trigger MG Exacerbations, European Study Shows